The Full Wiki

More info on Tositumomab

Tositumomab: Wikis

Advertisements

Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.

Encyclopedia

From Wikipedia, the free encyclopedia

Tositumomab ?
Monoclonal antibody
Source Mouse
Target CD20
Identifiers
CAS number 192391-48-3
ATC code V10XA53 (sequential regimen with 131I form)
PubChem  ?
DrugBank BTD00085
Chemical data
Formula C 6416H9874N1688O1987S44  
Mol. mass 143859.7 g/mol
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.  ?
Legal status
Routes  ?

Tositumomab is a drug for the treatment of follicular lymphoma. It is a IgG2a anti-CD20 monoclonal antibody derived from immortalized mouse cells.

Tositumomab is applied in a sequential infusion followed by iodine (131I) tositumomab, which is the same antibody covalently bound to the radionuclide iodine-131 (131I).[1] 131I emits both beta and gamma radiation and decays with a half-life of 8 days.

Clinical trials have established the efficacy of the tositumomab/iodine (131I) tositumomab regimen in patients with relapsed or chemotherapy/rituxan refractory follicular lymphoma.

This drug combination is manufactured by Corixa (now GlaxoSmithKline). It sells in the U.S. under the trade name Bexxar.

There is some evidence that it may cause a smaller decrease in platelet counts than ibritumomab tiuxetan does.[2]

References

External links

  • Bexxar regimen entry in the public domain NCI Dictionary of Cancer Terms
Advertisements

Advertisements






Got something to say? Make a comment.
Your name
Your email address
Message